Immunomedics is introducing a new breast cancer drug: Trudolvy
Immunomedics is introducing a new breast cancer drug: Trudolvy
… Tredolvy: A new oncology drug from Immunomedics for metastatic triple-negative breast cancer …

Immunomedics’ Trodelvy (sacituzumab govitecan-hziy) Earns FDA Approval

Trodelvy: a new oncology product for breast cancer

John G. Baresky

Trodelvy is a landmark breast cancer drug

Oncologists now have another option to treat breast cancer patients. The FDA has approved Immunomedic’s Trodelvy (sacituzumab govitecan-hziy) with an indication for adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease.

Trodelvy is a monoclonal antibody

Trodelvy is targeted therapy. Once administered to a patient, it aims for the protein called trop-2 that is often found on the surface of numerous types of solid tumors. It attaches itself to the tumor and administers a toxic chemotherapy metabolite known as irinotecan that destroys cancer cells by damaging their DNA.

Triple-negative breast cancer has an elevated level of treatment challenges

Triple-negative breast cancer does not have any of the receptors that are commonly found in breast cancer. Triple-negative breast cancer tests negative for estrogen receptors, progesterone receptors and excess HER2 protein. This means it is not fueled by estrogen and progesterone hormones or by HER2 protein. It can not be effectively treated with hormonal therapy drugs or therapies targeting HER2 protein receptors.

  • Mastectomy
  • Chemotherapy
  • Radiation

Information about Immunomedics

Founded in 1982, Immunomedics (NASDAQ: IMMU) is based in Morris Plains, New Jersey. The company has substantial experience and resources centered on antibody conjugation, antibody engineering, proprietary CDR-grafting methods, antibody production and formulation, immunochemistry, molecular biology, peptide chemistry, protein engineering and synthetic organic chemistry. It specializes in autoimmune and oncology therapeutic research and advanced product innovation.

The FDA continues to approve new and critically needed therapies

While COVID-19 engulfs the global healthcare community and numerous government authorities, the FDA continues to admirably fulfill its responsibilities. It is not only dealing with a viral pandemic it is evaluating a sizable number of advanced therapies. In the last several weeks it has approved:

  • AstraZeneca’s and Merck’s Koselugo (selumetinib)
  • Bristol Myers Squibb Opdivo (nivolumab) and Yervoy (ipilimumab)- (a 4th indication)
  • Bristol Myers Squibb Zeposia (ozanimod)
  • Seattle Genetics Tukysa (tucatinib)
  • Seqirus Audenz (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted)

Written by

Authentic, fact-based healthcare content marketing writing for medical, business, academic, patient and consumer audiences

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store